Kura Oncology (KURA) Share-based Compensation (2014 - 2026)
Kura Oncology (KURA) posted quarterly Share-based Compensation of $69000.0 for Q1 2026, down 99.12% year-over-year from $7.8 million in Q1 2025, and down 99.39% quarter-over-quarter from $11.4 million in Q4 2025.
Kura Oncology (KURA) Share-based Compensation (2014 - 2026) Analysis & Trends
Kura Oncology (KURA) has reported Share-based Compensation for 13 consecutive years, with $69000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation fell 99.12% year-over-year to $69000.0; the TTM figure through Mar 2026 stood at $19.8 million (down 28.95% YoY), while the FY2025 annual figure was $37.1 million, down 15.66% from the prior year.
- Share-based Compensation slipped to $69000.0 in Q1 2026 per KURA's latest filing, from $11.4 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $41.0 million in Q3 2025 and bottomed at -$15.1 million in Q4 2022.
- Historically, Share-based Compensation has averaged $5.4 million across 5 years, with a median of $3.0 million in 2024.
- Annual changes were most pronounced in 2022 — Share-based Compensation plunged 335.95% — and 2024, when it jumped 9809.52%.
- Kura Oncology's Share-based Compensation stood at -$15.1 million in 2022, then jumped by 147.48% to $7.2 million in 2023, then advanced by 20.43% to $8.6 million in 2024, then soared by 31.53% to $11.4 million in 2025, then sank by 99.39% to $69000.0 in 2026.
- Business Quant data shows KURA's Share-based Compensation at $69000.0 in Q1 2026, $11.4 million in Q4 2025, and $41.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Kura Oncology | 966.11 Mn | 966.11 Mn | 20.63 Mn | 8.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.21 Mn |
| Jun 30, 2026 | 8.21 Mn |
| Mar 31, 2026 | 69,000.00 |
| Mar 31, 2026 | 69,000.00 |
| Dec 31, 2025 | 11.35 Mn |
| Dec 31, 2025 | 11.35 Mn |
| Sep 30, 2025 | 41.00 Mn |
| Sep 30, 2025 | 41.00 Mn |
| Jun 30, 2025 | 515,000.00 |
| Jun 30, 2025 | 515,000.00 |
| Mar 31, 2025 | 7.84 Mn |
| Mar 31, 2025 | 7.84 Mn |
| Dec 31, 2024 | 8.63 Mn |
| Dec 31, 2024 | 8.63 Mn |
| Sep 30, 2024 | 8.32 Mn |
| Sep 30, 2024 | 8.32 Mn |
| Jun 30, 2024 | 3.04 Mn |
| Jun 30, 2024 | 3.04 Mn |
| Mar 31, 2024 | 2.56 Mn |
| Mar 31, 2024 | 2.56 Mn |